Patent ID: 8821877

Claim:
A method of potentiating HIV-1 inhibitory activity of a small molecule CCR5 receptor antagonist in an HIV-1-infected subject who has been administered, or will be administered, the small molecule CCR5 receptor antagonist in the treatment of the subject's HIV-1 infection, comprising administering to the subject an HIV-1 inhibitory amount of an anti-CCR5 receptor monoclonal antibody, wherein the amounts of the anti-CCR5 receptor monoclonal antibody and the small molecule CCR5 receptor antagonist combined, produces a synergistic antiviral effect on treating the HIV-1 infection, thereby potentiating the HIV-1 inhibitory activity of the small molecule CCR5 receptor antagonist, wherein the anti-CCR5 receptor monoclonal antibody is PRO 140, said PRO 140 comprising (i) two light chains, each light chain comprising the expression product of the plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising the expression product of either the plasmid designated pVg4:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or the plasmid designated pVg4:HuPRO140 (mut B+D+I)-VH (ATCC Deposit Designation PTA-4099) and wherein the small molecule CCR5 receptor antagonist is (1-[(4,6-dimethyl-5-pyrimidinyl) carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyli-4-methylpiperidine) (UK-427,857) having the structure: TAK-779 having the structure: where Y=-CH 2 , X=-Cl, R1=-CH 3 TAK-652 having the structure: or GW873140.